G3 Vision Labs

G3 Vision is a clinical-stage biotechnology company dedicated to the development of innovative therapies for ophthalmic conditions, with a primary focus on presbyopia. The company was founded by a team of industry veterans, including former executives from Aerie Pharmaceuticals, who bring extensive experience in ophthalmic drug development and commercialization. G3 Vision's lead candidate, G3V-201, is a novel small molecule eye drop designed to improve near vision by modulating the eye's accommodative response. By targeting the muscarinic acetylcholine receptor, the company aims to provide a more effective and better-tolerated alternative to existing miotic treatments. G3 Vision is currently advancing its pipeline through clinical trials to address the significant unmet need in age-related vision impairment.